7. Merck & Co. Inc. (NYSE:MRK)
Number of Hedge Fund Holders: 101
Supplied Share-Price Snapshot: $146.11, down 1.31%
Keytruda Funds the Present as New Medicines Build the Future
Merck & Co., Inc. (NYSE: MRK) faces a familiar pharmaceutical industry dilemma on an unusually large scale. Its leading cancer franchise continues to generate substantial revenue, but management must build additional growth engines before patent-related competition places greater pressure on that business. For investors examining pharmaceutical stocks, the company’s present earnings strength and its longer-term replacement pipeline deserve equal attention.
Third-quarter 2026 sales increased 5% year over year to $18.1 billion. Keytruda and Keytruda Qlex generated $8.6 billion, up 6%, accounting for nearly half of total revenue. Other businesses supplied encouraging growth. Winrevair, a treatment for pulmonary arterial hypertension, recorded $694 million in sales, an increase of 93%, while animal health sales reached $1.7 billion. The figures demonstrate the scale of the existing oncology franchise while showing that newer products are beginning to make more meaningful contributions.
The patent calendar gives that diversification urgency. Company disclosures indicate that U.S. biosimilar competition could begin in December 2028 when Keytruda’s primary compound patent expires, although other patents and potential litigation complicate the timeline. Acquisitions, new indications, and clinical development can broaden future revenue, but projected opportunities still need to become approved medicines with sustained commercial demand. For long-term healthcare investors, the key issue is whether the emerging portfolio can grow fast enough to absorb future pressure on the company’s largest franchise.
Ranking Rationale
Merck & Co., Inc. (NYSE: MRK) ranks seventh with 101 hedge fund holders. Substantial oncology revenue, rapid Winrevair growth, and an established animal health business support its inclusion, while the approaching Keytruda patent transition remains the defining strategic risk.
